ROZEREM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROZEREM (ROZEREM).
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; modulates circadian rhythm and sleep-wake cycle.
| Metabolism | Primarily hepatic via CYP1A2 (major), minor via CYP2C9 and CYP3A4 |
| Excretion | Primarily renal (about 84% of total clearance), with approximately 70-80% of an oral dose excreted in urine as glucuronide conjugates of ramelteon and its active metabolite M-II. Fecal excretion accounts for about 4%. |
| Half-life | Ramelteon: 1-2.6 hours. Active metabolite M-II: 2-5 hours. Clinical context: Short half-life supports use for sleep initiation without significant next-day residual effects. |
| Protein binding | Ramelteon: ~82% bound to albumin. M-II: ~70% bound to albumin. |
| Volume of Distribution | Ramelteon: Vd ≈ 73.6 L (approximately 1.0 L/kg in healthy adults, assuming 70 kg). Distribution primarily into total body water. |
| Bioavailability | Oral: Rapidly absorbed, absolute bioavailability approximately 1.8% due to extensive first-pass metabolism. Administration with high-fat meal reduces AUC by 31% and Cmax by 22%. |
| Onset of Action | Oral: Within 30 minutes (based on sleep latency reduction in clinical trials). |
| Duration of Action | Oral: 6-8 hours for sleep maintenance; clinical duration supports once-nightly dosing at bedtime. |
8 mg orally once daily, 30 minutes before bedtime, not to exceed 8 mg per day.
| Dosage form | TABLET |
| Renal impairment | For GFR < 50 mL/min: use with caution; no specific dose adjustment recommended, but exposure increased in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): use with caution; no specific dose adjustment recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No dose adjustment required; however, elderly patients may be more sensitive to sedative effects; monitor for daytime impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROZEREM (ROZEREM).
| Breastfeeding | Ramelteon is excreted in rat milk; human data not available. M/P ratio unknown. Caution advised due to potential for infant sedation or growth effects. Consider alternative sleep agents with more safety data. |
| Teratogenic Risk | Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 200 mg/kg/day (120 times the MRHD) in rats and 400 mg/kg/day (480 times the MRHD) in rabbits, but embryo-fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Risk to fetus cannot be ruled out; use only if potential benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to ramelteon or any component of the formulation","Concomitant use with fluvoxamine (strong CYP1A2 inhibitor)"]
| Precautions | ["Angioedema","Severe allergic reactions","Sleep-driving and other complex behaviors","Behavioral and psychiatric effects (e.g., hallucinations, depression, suicidal ideation)","Hormonal effects (e.g., decreased testosterone, increased prolactin)"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal sedation, dizziness, and somnolence. No specific fetal monitoring required; routine prenatal care is adequate. |
| Fertility Effects | In animal studies, no effects on fertility or reproductive performance in male and female rats at doses up to 160 mg/kg/day (100 times MRHD). Human data on fertility effects are lacking. |